Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Augmenting Moieties for Anti-Inflammatory Compounds

a technology of anti-inflammatory compounds and moieties, which is applied in the field of anti-inflammatory compounds, can solve the problems of ulcer perforation, death, and limiting the use of nsaid therapy, and achieve the effect of improving the potency and safety of anti-inflammatory compounds

Inactive Publication Date: 2017-02-16
RUTGERS THE STATE UNIV +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a way to make anti-inflammatory drugs more effective and safer. This is done by combining different parts of the drug molecule with each other. The resulting combination has a stronger effect than the original drug alone. This can improve the activity of the drug and make it easier to treat inflammation.

Problems solved by technology

These effects are dose-dependent and, in many cases, severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death, thereby limiting the use of NSAID therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Augmenting Moieties for Anti-Inflammatory Compounds
  • Augmenting Moieties for Anti-Inflammatory Compounds
  • Augmenting Moieties for Anti-Inflammatory Compounds

Examples

Experimental program
Comparison scheme
Effect test

examples

Materials and Methods

[0050]All reactants and solvents used were of the highest purity commercial grade and were employed without further purification. All amino acids used herein were the L-amino acids and were purchased from Sigma-Aldrich (Saint Louis, Mo.). The 2-(2-methoxynaphthalene-6-yl) propanoic acid (naproxen) used was the (S)-enantiomer. All other reagents were used as racemates, unless otherwise noted. All reactions were performed in oven-dried apparatus under a nitrogen atmosphere, unless otherwise noted. All solvents used were anhydrous, unless otherwise noted. NMR spectra were recorded on a Bruker multinuclear spectrometer and chemical shifts are reported as ppm using tetramethylsilane (TMS) as an internal standard. 1H NMR spectra were recorded at 500 MHz, while 13C NMR spectra were recorded at 125 MHz. Elemental analyses were performed at Intertek (Whitehouse, N.J.). All thin layer chromatography (TLC) was performed on Analtech silica gel plates (250 microns).

Biologica...

examples of aspect i

[0054]The bifunctional and tri-functional conjugates of Aspect I of the invention were prepared and tested in a standard in vivo MEVM assay for their efficacy compared to that of the parent terpene, amino acid, polyamine, or vanilloid from which each was assembled. Terpene inflammation suppression scores (average of TPA-induced and CEES-induced injuries) ranged from myrtenol (6%), thymol (14%), carvacrol (15%), cumyl alcohol (16%), geraniol (35%), menthol (38%), perillyl alcohol (43%), and farnesol (69%). All terpenes, except farnesol, had inflammation suppression scores less than 45%. The inflammation scores of typical vanilloids were similarly low and none exceeded 40%, e.g., vanillin (11%), vanillyl alcohol (31%), and vanillylamine (35%). In this assay inflammation suppression scores for the amino acids and the polyamines were under 30%. The traditional NSAIDs were under 40% in inflammation suppression scores, e.g., ibuprofen (−23%, an irritant / inflammation inducer), S-naproxen (...

examples of aspect ii

[0118]Synergism of anti-inflammatory responses by anti-inflammatory agents covalently coupled to amino acids (Aspect II) was demonstrated by preparation of the S-naproxen-valine conjugate, and screening it in the MEVM against CEES challenge. MEVM is a standard in vivo assay for assessment of anti-inflammatory potential in addressing chemically-induced injury to rodent skin. CEES is one of the inflammation inducers employed in the MEVM assay. A compound of the invention, Formula (IV-acid) (NDH 4476) provided four times better inflammation suppression (44%) than naproxen itself under the same conditions. The corresponding ethyl ester analog (IV-ethyl ester) (NDH 4535) was equipotent but the 3.3-dimethylbutyl ester (IV-3,3-dimethylbutyl-) (NDH 4596) was superior at 52% inflammation suppression. The latter molecule also was an inhibitor of AChE displaying anti-cholinergic activity with an IC50 of 18.6 μM.

[0119]The phenylalanine conjugate of S-naproxen (esterified as the 3,3-dimethylbuty...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Augmented or synergized anti-inflammatory constructs are disclosed including anti-inflammatory amino acids covalently conjugated with other anti-inflammatory molecules such as nonsteroidal anti-inflammatory drugs, vanilloids and ketone bodies. Further conjugation with a choline bioisostere or an additional anti-inflammatory moiety further augments the anti-inflammatory activity.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation-In-Part of U.S. patent application Ser. No. 14 / 776,857, filed on Sep. 15, 2015, which is the U.S. National Phase of International Patent Application Serial No. PCT / US14 / 28329, filed on Mar. 14, 2014, which claims the benefit of priority under 35 U.S.C. 119(e) of U.S. Provisional Application No. 61 / 790,870, filed on Mar. 15, 2013, and of U.S. Provisional Application No. 61 / 793,842, filed on Mar. 15, 2013. The disclosures of all of the above are incorporated herein by reference in their entireties.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under Grant No. U54AR055073 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The invention is directed to anti-inflammatory compounds which are synergistically enhanced in their anti-inflammatory activity through conjugatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C237/06C07D209/18C07D207/16C07C271/12
CPCC07C237/06C07D207/16C07D209/18C07C271/12A61K47/542A61K47/543A61K47/55
Inventor LASKIN, JEFFREY D.HECK, DIANE E.LACEY, CARL J.HEINDEL, NED D.YOUNG, SHERRI C.
Owner RUTGERS THE STATE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com